UNSPSC 51362008: Zolazepam hydrochloride

This classification denotes a sedative and hypnotic with the molecular formula C15H15FN4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45SJ093Q1N, chemically known as 4-(o-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1h)-one monohydrochloride but more generally known as zolazepam hydrochloride, which bears US NIH Compound Identifier 71416. Most nations, for tariff and trade purposes, schedule zolazepam hydrochloride under HS 29339940 and SITC 51577.

As of Q4 2014, ZOLAZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zolazepam hydrochloride bears US NLM identifiers UMLS ID C0917859 and NCI Concept Code C76953. SMILES: CC1C2C(N(N1)C)N(C(=O)CN=C2C3CCCCC3F)C.CL.

UNSPSC 51362008 Zolazepam hydrochloride is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local solicitations tagged under this code show minimal alignment with the substance itself. The source shows three recent opportunities across pharmaceutical procurement, none of which centers on zolazepam specifically. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued an RFI exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products. The mismatch between the code's nominal scope and actual procurement activity suggests the code sees little relevant recent activity in state and local buying.

Geographic activity is scattered across Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative vehicle extending reach across participating jurisdictions including Oregon. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) represents the closest match to emergency pharmaceutical supply chains, though naloxone is not zolazepam. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) covers broader generic pharmaceuticals through a cooperative purchasing model serving state and local facilities, while the Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) is exploratory market intelligence for direct-to-manufacturer prescription fulfillment rather than a live procurement. The code does not show a coherent procurement pattern around the substance named; vendors evaluating this code should verify whether state and local buying actually tracks to zolazepam or whether the tagging reflects broader pharmaceutical categorization that does not match specific-substance procurement.